Zurück zur Übersicht
| Journal of the American Academy of Dermatology. 2014 Oct 16. pii: S0190-9622(14)01897-0. doi: 10.1016/j.jaad.2014.09.002. pmc: PMC4254519. mid: NIHMS627049 |
| Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. |
| Sanlorenzo M1, Choudhry A2, Vujic I3, Posch C4, Chong K5, Johnston K6, Meier M7, Osella-Abate S8, Quaglino P9, Daud A10, Algazi A11, Rappersberger K12, Ortiz-Urda S13 |
 Author information
|
|
Abstract BACKGROUND: BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events. OBJECTIVE: We sought to investigate the cutaneous safety profile of BRAFi versus BRAFi and MEKi combination regimens. METHODS: We performed a retrospective cohort study, collecting data from 44 patients with melanoma treated either with BRAFi (vemurafenib or dabrafenib) or BRAFi and MEKi combination regimens (vemurafenib + cobimetinib or dabrafenib + trametinib). Patient characteristics, and the occurrence and severity of cutaneous adverse events, are described. RESULTS: The development of cutaneous adverse events was significantly less frequent (P = .012) and occurred after longer treatment time (P = .025) in patients treated with BRAFi and MEKi combination regimen compared with patients treated with BRAFi monotherapy. Among patients who received both BRAFi and the combination of BRAFi and MEKi at different time points during their treatment course, the development of squamous cell carcinoma or keratoacanthoma was significantly less frequent when they received the combination regimen (P = .008). Patients receiving vemurafenib developed more cutaneous adverse events (P = .001) and in particular more photosensitivity (P = .010) than patients who did not. LIMITATIONS: There were a limited number of patients. CONCLUSION: Combination regimen with BRAFi and MEKi shows fewer cutaneous adverse events and longer cutaneous adverse event-free interval compared with BRAFi monotherapy. |
|
Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. |
|
KEYWORDS: cutaneous adverse event, histology, inflammation, rash, squamous cell carcinoma, therapy |
|
Publikations ID: 25440439 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
